Edition:
United States

Osiris Therapeutics Inc (OSIR.OQ)

OSIR.OQ on NASDAQ Stock Exchange Global Market

5.10USD
2:34pm EST
Change (% chg)

$0.06 (+1.19%)
Prev Close
$5.04
Open
$4.98
Day's High
$5.17
Day's Low
$4.98
Volume
9,265
Avg. Vol
41,808
52-wk High
$7.74
52-wk Low
$3.55

Latest Key Developments (Source: Significant Developments)

Osiris Therapeutics files for non-timely 10-Q with U.S. SEC - SEC filing
Tuesday, 9 Aug 2016 06:27pm EDT 

Osiris Therapeutics Inc : Says files for non-timely 10-Q with U.S. SEC - SEC filing . Says is in process of completing accounting review of revenue recognition under contracts with distributors . Does not expect to file Q2 2016 quarterly report within the extension period of five calendar days provided under rule 12B-25 Source: (http://bit.ly/2b4EKXC ) Further company coverage: [OSIR.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Osiris Therapeutics says names David Dresner interim CEO
Friday, 10 Jun 2016 04:08pm EDT 

Osiris Therapeutics Inc : Says it has appointed David Dresner as interim president and chief executive officer .Dresner is expected to serve in that capacity until board completes its search for a permanent CEO.  Full Article

Osiris Therapeutics says being investigated by NY Attorney's Office
Friday, 27 May 2016 05:02pm EDT 

Osiris Therapeutics : Advised by U.S. Attorney's Office for Southern District of New York that criminal investigation has been opened into co .Investigation by U.S. Attorney'S Office related to matters also under investigation, as previously disclosed, by the SEC.  Full Article

Osiris Therapeutics, Inc announces leadership change
Thursday, 3 Mar 2016 04:00pm EST 

Osiris Therapeutics, Inc:Confirms dwayne Montgomery, as president and chief executive officer, and the election of thomas m. brandt to the board of directors.  Full Article

Osiris Therapeutics Inc announces leadership transition
Wednesday, 3 Feb 2016 04:30pm EST 

Osiris Therapeutics Inc:Dwayne Montgomery, its current Chief Business Officer, has been appointed today to serve as Interim Chief Executive Officer.Montgomery will replace Lode Debrabandere who today has announced his resignation for personal reasons from Osiris.  Full Article

Osiris Therapeutics, Inc announces special dividend of $0.20 per share
Thursday, 17 Sep 2015 08:00am EDT 

Osiris Therapeutics, Inc:Announces special dividend.Sets cash dividend of $0.20 per share.  Full Article

Osiris Therapeutics, Inc appoints new chief financial officer
Thursday, 17 Sep 2015 08:00am EDT 

Osiris Therapeutics, Inc:Appoints new chief financial officer and chief business officer.Says gregory law appointed CFO.  Full Article

BRIEF-Osiris Therapeutics says commenced steps to terminate enrollment in OTI-15-01 phase III clinical trial

* says on October 14, 2016, company commenced steps to terminate enrollment in its OTI-15-01 phase III clinical trial